Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jenny Rinke

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Best Practice & Research. Clinical Haematology|October 11, 2020
CML - Not only BCR-ABL1 mattersJenny Rinke, Andreas Hochhaus, Thomas Ernst
Annals of Hematology|June 25, 2020
Durable remission with ruxolitinib in a chronic neutrophilic leukemia patient harboring a truncation and membrane proximal CSF3R compound mutationAnna Hinze, Jenny Rinke, Andreas Hochhaus, et al.
Cells|July 12, 2020
EZH2 in Myeloid MalignanciesJenny Rinke, Andrew Chase, Nicholas C P Cross, et al.
Journal of Thrombosis and Haemostasis : JTH|April 18, 2026
Dysregulation of HIF-1α-regulated and thrombo-inflammatory genes may contribute to thrombotic risk in patients with BCR::ABL1-negative myeloproliferative neoplasmsOlga Morath, Therese Wolfrum, Carl Crodel, et al.
Leukemia|December 15, 2019
Molecular-defined clonal evolution in patients with chronic myeloid leukemia who were exposed to ionizing radiation following the Chernobyl nuclear disasterThomas Ernst, Jenny Rinke, Julia Hagen, et al.
Clinical Chemistry|April 18, 2013
Genotyping of 25 leukemia-associated genes in a single work flow by next-generation sequencing technology with low amounts of input template DNAJenny Rinke, Vivien Schäfer, Mathias Schmidt, et al.
Annals of Hematology|March 17, 2016
Continuous molecular remission and regression of side effects after discontinuation of salvage therapy with sorafenib and donor lymphocyte infusions in a young patient with relapsed AMLJana Ernst, Vivien Schäfer, Jenny Rinke, et al.
Leukemia|July 4, 2024
Treatment-free remission after third-line therapy with asciminib in chronic myeloid leukemia with an atypical e19a2 BCR::ABL1 transcript and T315I mutationPhilipp Ernst, Jenny Rinke, Georg-Nikolaus Franke, et al.
Journal of Cancer Research and Clinical Oncology|September 16, 2017
Only SETBP1 hotspot mutations are associated with refractory disease in myeloid malignanciesNils Winkelmann, Vivien Schäfer, Jenny Rinke, et al.
Annals of Hematology|April 27, 2025
Molecular predictors of venous and arterial thrombotic events in patients with myelofibrosisOlga Morath, Jenny Rinke, Annabell Walter, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Best Practice & Research. Clinical Haematology|October 11, 2020
CML - Not only BCR-ABL1 mattersJenny Rinke, Andreas Hochhaus, Thomas Ernst
Annals of Hematology|June 25, 2020
Durable remission with ruxolitinib in a chronic neutrophilic leukemia patient harboring a truncation and membrane proximal CSF3R compound mutationAnna Hinze, Jenny Rinke, Andreas Hochhaus, et al.
Cells|July 12, 2020
EZH2 in Myeloid MalignanciesJenny Rinke, Andrew Chase, Nicholas C P Cross, et al.
Journal of Thrombosis and Haemostasis : JTH|April 18, 2026
Dysregulation of HIF-1α-regulated and thrombo-inflammatory genes may contribute to thrombotic risk in patients with BCR::ABL1-negative myeloproliferative neoplasmsOlga Morath, Therese Wolfrum, Carl Crodel, et al.
Leukemia|December 15, 2019
Molecular-defined clonal evolution in patients with chronic myeloid leukemia who were exposed to ionizing radiation following the Chernobyl nuclear disasterThomas Ernst, Jenny Rinke, Julia Hagen, et al.
Clinical Chemistry|April 18, 2013
Genotyping of 25 leukemia-associated genes in a single work flow by next-generation sequencing technology with low amounts of input template DNAJenny Rinke, Vivien Schäfer, Mathias Schmidt, et al.
Annals of Hematology|March 17, 2016
Continuous molecular remission and regression of side effects after discontinuation of salvage therapy with sorafenib and donor lymphocyte infusions in a young patient with relapsed AMLJana Ernst, Vivien Schäfer, Jenny Rinke, et al.
Leukemia|July 4, 2024
Treatment-free remission after third-line therapy with asciminib in chronic myeloid leukemia with an atypical e19a2 BCR::ABL1 transcript and T315I mutationPhilipp Ernst, Jenny Rinke, Georg-Nikolaus Franke, et al.
Journal of Cancer Research and Clinical Oncology|September 16, 2017
Only SETBP1 hotspot mutations are associated with refractory disease in myeloid malignanciesNils Winkelmann, Vivien Schäfer, Jenny Rinke, et al.
Annals of Hematology|April 27, 2025
Molecular predictors of venous and arterial thrombotic events in patients with myelofibrosisOlga Morath, Jenny Rinke, Annabell Walter, et al.
Pageof 3